Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women

REFERENCES

• Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000;84:15–21.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Stahlberg S, Manthey T, et al. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception 2008;78:384–91.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343:d6423.
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: Results of the MEGA case-control study. BMJ 2009;339:b2921.
   PubMed Web of Science ®Google Scholar
• Martínez F, Ramírez I, Pérez-Campos E, et al. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care 2012;17:7–29.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Kuhl H. Metabolic and clinical effects of progestogens. Eur J Contracept Reprod Health Care 2006; 11:153–61.
   PubMed Web of Science ®Google Scholar
• Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010;126:5–11.
   PubMed Web of Science ®Google Scholar
• van Vliet HA, Bertina RM, Dahm AE, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008;6:346–51.
   PubMed Web of Science ®Google Scholar
• WHO Task Force on Oral Contraceptives. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Task Force on Oral Contraceptives – WHO Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland. Br J Obstet Gynaecol 1991;98:1117–28.
   PubMedGoogle Scholar
• Middeldorp S, Meijers JC, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study. Thromb Haemost 2000;84:4–8.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009;339:b2890.
   PubMed Web of Science ®Google Scholar
• Hannaford PC. Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res 2011; 127(Suppl. 3):S30–4.
   Google Scholar
• Edelman A, Lew R, Cwiak C, et al. Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women. Contraception 2007;75:450–3.
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Carl J, Gopalakrishnan I, et al. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception 2004;70:281–7.
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Portman DJ, Hait H, Reape KZ. Adding low-dose estrogen to the hormone-free interval: Impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive. Contraception 2009;79:350–5.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency and Committee for Medical Products for Human Use. Guideline on clinical investigation of steroid contraceptives in women. Accessed 24 March 2014 from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003349.pdf
   Google Scholar
• Wiegratz I, Kutschera E, Lee JH, et al. Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 2003;67:361–6.
   PubMed Web of Science ®Google Scholar
• Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: Conclusions from a large randomized multicenter study. Contraception 2003; 67:173–85.
   PubMed Web of Science ®Google Scholar
• Garattini S, Bertele V. Adjusting Europe's drug regulation to public health needs. Lancet 2001;358:64–7.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks – CHMP endorses PRAC recommendation. Accessed 24 March 2014 from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/11/WC500155455.pdf
   Google Scholar
• Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73:229–34.
   PubMed Web of Science ®Google Scholar
• Davis M. Evaluation of the long-term safety of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo. Contraception 2007;76: 172(abstract P42).
   Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?Acta Obstet Gynecol Scand 2002; 81:482–90.
   PubMed Web of Science ®Google Scholar
• Rad M, Kluft C, de Kam ML, et al. Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use. Eur J Contracept Reprod Health Care 2011;16:85–94.
   PubMed Web of Science ®Google Scholar